KT-333

GlobalData analyzes drug development, including KT-333, a PROTAC targeting STAT3 for various cancers and disorders, developed by Kymera Therapeutics using the Pegasus platform. Kymera focuses on protein degradation therapies, with a pipeline including IRAK4, IRAKIMiD, STAT3, and MDM2 for diverse conditions.

Kymera Therapeutics advances its immunology pipeline with KT-621 (STAT6) Phase 1 trial initiation, expecting data by mid-2025. Sanofi expands KT-474 (IRAK4) Phase 2 trials for HS and AD, aiming for completion by mid-2026. KT-295 (TYK2) selected for Phase 1 trials in 2025. Company shifts focus to immunology, with $911M cash extending runway to mid-2027.

The T-cell malignancies market is expanding due to increased incidence, treatment advancements, and strategic partnerships. Key companies like Corvus Pharmaceuticals, Bristol-Myers Squibb, and Kymera Therapeutics are developing over 80 pipeline therapies. Notable drugs include Soquelitinib (Phase III), MB 105 (Phase II), and KT-333 (Phase I). Regulatory milestones and positive trial results are driving progress in this field.

Kymera Therapeutics' Phase 1 trial of KT-333, targeting STAT3, shows promising antitumor activity in hematological cancers, including complete responses in Hodgkin’s lymphoma. The drug is well-tolerated, with potential for curative stem cell transplants post-treatment. Encouraging data supports its therapeutic potential across various malignancies.

KT-333, a VHL-based STAT3 PROTAC degrader, targets STAT3, a transcriptional regulator linked to cancers and inflammatory diseases. Its structure, related to Kymera's I-241, awaits peer-reviewed disclosure. Physico-chemical properties and molecular details are provided.